Themis Medicare Ltd

Themis Medicare Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.21, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.95, suggesting it can cover its short-term obligations but with limited excess capacity. Free cash flow stands at INR 197.33 million, which is lower than the operating cash flow of INR 347.10 million, primarily due to capital expenditures of INR 154.26 million. Profitability metrics show a return on equity (ROE) of 7.41% and a return on assets (ROA) of 5.07%. These figures are below the typical thresholds for high-performing pharmaceutical firms, indicating that the company is generating returns, but not at a level that would be considered exceptional within the industry. The operating margin, calculated as operating income of INR 391.19 million on revenue of INR 4,055.12 million, is 9.65%, which is in line with the industry median of 10.2%. The company operates through a single segment, Pharmaceuticals, and is primarily focused on the Indian market. Revenue concentration is not disclosed by region, but the company's operations are based in India, suggesting a significant exposure to the domestic market. There is no indication of international revenue diversification in the provided data. Growth trajectory for the current fiscal year is modest, with no specific revenue growth rate provided. However, the company's operating cash flow and net income have shown positive trends, indicating a stable financial performance. The outlook for the next fiscal year is not explicitly stated, but the company's capital expenditures suggest a focus on maintaining and possibly expanding its production capabilities. Risk factors include a medium liquidity risk, as the company has a current ratio of 1.95, which is adequate but not robust. The risk of dilution is assessed as low, with no significant changes in shares outstanding between basic and diluted shares. The company's net cash position is negative after subtracting total debt, which could pose a challenge if cash flow from operations is disrupted. Recent events include the company's continued focus on its core pharmaceutical manufacturing activities, with no major acquisitions or divestitures reported. The company's recent filings and transcripts do not indicate any significant changes in strategy or operations, suggesting a stable business environment.